Monomethyl Fumarate Challenges Multiple Sclerosis
A novel bioequivalent of dimethyl fumarate (Tecfidera) may soon be offering another treatment option for patients with multiple sclerosis.
Read More
Greater Benefits for Relapsing-Remitting MS Found with HSCT Therapy
For patients in the HSCT group, disease-modifying therapies use was discontinued, followed by variable washout periods before admission for HSCT.
Elevated Acrolein Levels May Be a Future Diagnostic Tool in Multiple Sclerosis
Acrolein levels were significantly elevated in urine and serum in patients with multiple sclerosis compared to healthy controls.
Ocrelizumab Shows Superiority to or Comparability with Other Multiple Sclerosis Treatments
Ocrelizumab demonstrated superiority to or comparability with 14 other disease-modifying therapies currently approved by the European Medicines Agency.